LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI Tool for Automatic Colorectal Cancer Tissue Analysis Outperforms Prior Methods

By LabMedica International staff writers
Posted on 26 Oct 2023
Image: A new AI tool outperforms prior methods in colorectal cancer analysis (Photo courtesy of 123RF)
Image: A new AI tool outperforms prior methods in colorectal cancer analysis (Photo courtesy of 123RF)

Colorectal Cancer (CRC) ranks as the third most prevalent and the second most lethal cancer. Catching it early and treating it promptly are extremely important. While machine vision technologies have seen remarkable improvements in automatically classifying types of cancer, they largely rely on deep neural networks with millions of parameters fine-tuned for diagnostic and prognostic tasks. Even though deep learning has shown extraordinary capabilities, healthcare professionals still have to inspect biopsied tissue samples to verify the diagnosis and assess the stage of the tumor. To advance this field further, scientists have now introduced an artificial intelligence (AI) solution specifically designed for automated analysis of colorectal cancer tissue that outperforms previous techniques.

The refined neural network developed by researchers from the University of Jyväskylä (Jyväskylä, Finland) has set new performance benchmarks in colorectal cancer tissue analysis. The AI-based system offers a more accurate and quicker way to categorize tissue samples of colorectal cancer from microscope slides. This advancement could significantly ease the work burden on histopathologists, thus enabling faster and more precise prognoses and diagnoses. Despite the promising results, it is important to be cautious while incorporating AI into medical practice.

As AI technologies move closer to becoming a standard part of clinical procedures, it becomes increasingly vital that they go through rigorous clinical validation. This is to ensure that the results they produce are consistently in line with established clinical norms. In a move encouraging collaborative development, the researchers are making this trained neural network publicly available. Their aim is to accelerate progress in the field by allowing scientists, researchers, and developers from around the world to further refine the tool and explore its various potential applications.

“By granting universal access, the aim is to fast-track breakthroughs in colorectal cancer research,” said Fabi Prezja, who was responsible for the design of the method.

Related Links:
University of Jyväskylä 

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Urine Chemistry Control
Dropper Urine Chemistry Control

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more